CURE’s lung cancer page is an extensive resource of cancer information featuring the latest lung cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on lung cancer.
April 29th 2025
The Ventana TROP2 RxDx Device, a computational companion diagnostic, was granted breakthrough device designation by the FDA in non–small cell lung cancer.
Tagrisso Plus Chemo Approved by FDA for EGFR-Mutated NSCLC
February 16th 2024The Food and Drug Administration has approved Tagrisso plus platinum-based chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations.
Phase 2 Trial Assessing Novel TKI Begins in ALK-Positive NSCLC, Solid Tumors
February 12th 2024Researchers have initiated a phase 2 trial assessing a novel tyrosine kinase inhibitor that can potentially penetrate the central nervous system in patients with ALK-positive non-small cell lung cancer and other solid tumors.
Opdivo Plus Chemo Did Not Improve Progression in EGFR-Mutated NSCLC
February 8th 2024Treatment with Opdivo (nivolumab) and chemotherapy did not significantly improve progression-free survival when compared with chemotherapy alone among some patients with EGFR-mutated metastatic non-small-cell lung cancer.
Tagrisso After Chemoradiation Reduced Progression Risk in NSCLC
February 7th 2024Treatment with Tagrisso after chemoradiation resulted in patients with EGFR-mutant stage 3 non-small cell lung cancer being nearly three times less likely to experience disease progression when compared with those treated with Imfinzi or subject to observation.